Download MendeleyDiscovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations.
Thomson, C., Barton, P., Braybrooke, E., Colclough, N., Dong, Z., Evans, L., Floc'h, N., Guerot, C., Hargreaves, D., Khurana, P., Li, S., Li, X., Lister, A., McCoull, W., McWilliams, L., Orme, J.P., Packer, M.J., Swaih, A.M., Ward, R.A., Winlow, P., Ye, Y.(2024) J Med Chem 67: 8988-9027
- PubMed: 38770784
- DOI: https://doi.org/10.1021/acs.jmedchem.4c00227
- Primary Citation of Related Structures:
8PNZ, 8PO0, 8PO1, 8PO2, 8PO3, 8PO4 - PubMed Abstract:
Herein, we report the identification and optimization of a series of potent inhibitors of EGFR Exon20 insertions with significant selectivity over wild-type EGFR. A strategically designed HTS campaign, multiple iterations of structure-based drug design (SBDD), and tactical linker replacement led to a potent and wild-type selective series of molecules and ultimately the discovery of 36 . Compound 36 is a potent and selective inhibitor of EGFR Exon20 insertions and has demonstrated encouraging efficacy in NSCLC EGFR CRISPR-engineered H2073 xenografts that carry an SVD Exon20 insertion and reduced efficacy in a H2073 wild-type EGFR xenograft model compared to CLN-081 ( 5 ), indicating that 36 may have lower EGFR wild-type associated toxicity.
Organizational Affiliation:
AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
